These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 7753456

  • 1. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood.
    Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL.
    Thromb Haemost; 1988 Dec 22; 60(3):377-81. PubMed ID: 2853458
    [Abstract] [Full Text] [Related]

  • 3. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL.
    Semin Thromb Hemost; 1997 Dec 22; 23(1):83-90. PubMed ID: 9156415
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
    Kristensen HI, Ostergaard PB, Nordfang O, Abildgaard U, Lindahl AK.
    Thromb Haemost; 1992 Sep 07; 68(3):310-4. PubMed ID: 1332210
    [Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J.
    J Mal Vasc; 1987 Sep 07; 12 Suppl B():68-70. PubMed ID: 2834495
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay.
    Abildgaard U, Norrheim L, Larsen AE, Nesvold A, Sandset PM, Odegaard OR.
    Haemostasis; 1990 Sep 07; 20(4):193-203. PubMed ID: 2173672
    [Abstract] [Full Text] [Related]

  • 12. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S, Theaker J, Preston FE.
    Blood Coagul Fibrinolysis; 2000 Mar 07; 11(2):137-44. PubMed ID: 10759006
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL.
    Thromb Haemost; 1989 Jun 30; 61(3):357-62. PubMed ID: 2552604
    [Abstract] [Full Text] [Related]

  • 15. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin.
    Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG.
    Thromb Haemost; 1986 Dec 15; 56(3):243-6. PubMed ID: 3551180
    [Abstract] [Full Text] [Related]

  • 16. [Monitoring of plasma concentration of low molecular weight heparin--comparative evaluation with chromogenic and clotting assays].
    Katagiri H, Itoh S, Uchida T, Kawai Y, Watanabe K.
    Rinsho Byori; 1999 Nov 15; 47(11):1046-51. PubMed ID: 10590682
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.